AbbVie Company Insiders
ABBV Stock | USD 167.80 1.74 1.03% |
Slightly above 82 percent of AbbVie's insiders are selling. The analysis of the overall insider sentiment regarding AbbVie Inc suggests that a fairly large number of insiders are terrified. AbbVie employs about 50 K people. The company is managed by 38 executives with a total tenure of roughly 207 years, averaging almost 5.0 years of service per executive, having 1315.79 employees per reported executive.
Carlos Alban Chairman Vice Chairman, Chief Commercial Officer |
Robert Michael Chairman Vice Chairman, Finance and Commercial Operations and Chief Financial Officer |
AbbVie's Insider Buying Vs Selling
18
Selling | Buying |
Latest Trades
2024-03-20 | Nicholas Donoghoe | Disposed 21082 @ 176.3 | View | ||
2024-03-18 | Jeffrey Ryan Stewart | Disposed 58949 @ 178.79 | View | ||
2024-02-29 | Kevin K Buckbee | Disposed 5144 @ 176.65 | View | ||
2024-02-28 | Richard A Gonzalez | Disposed 138616 @ 177.27 | View | ||
2024-02-23 | Scott T Reents | Disposed 14140 @ 177.44 | View | ||
2024-02-21 | Azita Saleki-Gerhardt | Disposed 52870 @ 173.71 | View | ||
2024-01-23 | Kathy E. Manning | Acquired @ 167.51 | |||
2024-01-19 | Tommy Tuberville | Disposed @ 164.77 | |||
2023-12-26 | Nicholas Donoghoe | Disposed 2912 @ 154.72 | View | ||
2023-12-08 | Michael C. Burgess | Disposed @ 149.28 | |||
2023-11-20 | Tommy Tuberville | Disposed @ 138.31 | |||
2023-11-08 | Josh Gottheimer | Disposed @ 142.04 | |||
2023-10-24 | Greg Stanton | Disposed @ 146.31 | |||
2023-10-17 | Tommy Tuberville | Acquired @ 149.18 | |||
2023-09-28 | Robert J. Wittman | Disposed @ 152.25 | |||
2023-09-26 | Greg Stanton | Acquired @ 153.91 |
Monitoring AbbVie's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Acquired vs Disposed
Filed vs Not Filed
Insider sentiment refers to the collective sentiment or feeling of AbbVie's insiders - typically its officers, directors, and beneficial owners holding more than a certain percentage of the company's stock - about the future prospects of AbbVie Inc. This sentiment is often gauged based on the trading activities of these insiders. If insiders are purchasing more shares of their own company, it may be interpreted as a bullish sentiment, indicating that they believe AbbVie's stock will rise in value. Conversely, if insiders are selling shares, it might be seen as bearish, suggesting they expect the stock price to drop.
AbbVie |
AbbVie's Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with AbbVie's future performance. Based on our forecasts, it is anticipated that AbbVie will maintain a workforce of slightly above 50000 employees by May 2024.AbbVie's latest congressional trading
Congressional trading in companies like AbbVie Inc, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in AbbVie by those in governmental positions are based on the same information available to the general public.
2024-01-19 | Senator Thomas H Tuberville | Acquired Under $15K | Verify | ||
2023-09-26 | Representative Greg Stanton | Acquired Under $15K | Verify | ||
2023-08-07 | Representative Michael Patrick Guest | Acquired Under $15K | Verify | ||
2023-04-03 | Senator Tommy Tuberville | Acquired Under $15K | Verify | ||
2022-08-05 | Representative Dwight Evans | Acquired Under $15K | Verify | ||
2022-01-18 | Senator Thomas R. Carper | Acquired Under $15K | Verify | ||
2021-06-16 | Representative Marjorie Taylor Greene | Acquired Under $15K | Verify | ||
2021-02-16 | Representative Peter Meijer | Disposed Under $15K | Verify | ||
2020-12-22 | Representative Gilbert Cisneros | Acquired Under $15K | Verify | ||
2020-11-19 | Representative Kenny Marchant | Acquired $15K to $50K | Verify | ||
2020-11-15 | Representative Richard W. Allen | Acquired $15K to $50K | Verify | ||
2020-08-21 | Senator Jerry Moran | Acquired Under $15K | Verify | ||
2020-05-08 | Representative Steve Chabot | Acquired Under $15K | Verify | ||
2020-04-14 | Senator David A Perdue , Jr | Acquired $15K to $50K | Verify | ||
2020-04-07 | Senator Kelly Loeffler | Acquired $15K to $50K | Verify | ||
2019-08-13 | Representative Dean Phillips | Acquired Under $15K | Verify | ||
2019-07-02 | Representative Carol Devine Miller | Acquired $15K to $50K | Verify | ||
2019-03-25 | Representative Nicholas Van Taylor | Acquired $15K to $50K | Verify | ||
2018-09-18 | Representative Gary Palmer | Acquired Under $15K | Verify | ||
2015-03-10 | Senator Sheldon Whitehouse | Acquired Under $15K | Verify |
AbbVie Management Team Effectiveness
The company has return on total asset (ROA) of 0.0807 % which means that it generated a profit of $0.0807 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.352 %, meaning that it created $0.352 on every $100 dollars invested by stockholders. AbbVie's management efficiency ratios could be used to measure how well AbbVie manages its routine affairs as well as how well it operates its assets and liabilities. At this time, AbbVie's Return On Capital Employed is fairly stable compared to the past year. Return On Equity is likely to climb to 0.65 in 2024, whereas Return On Tangible Assets are likely to drop 0.1 in 2024. At this time, AbbVie's Other Assets are fairly stable compared to the past year. Non Currrent Assets Other is likely to climb to about 6.9 B in 2024, whereas Non Current Assets Total are likely to drop slightly above 57.7 B in 2024.Common Stock Shares Outstanding is likely to climb to about 1.8 B in 2024. Net Income Applicable To Common Shares is likely to climb to about 14.3 B in 2024
AbbVie Workforce Comparison
AbbVie Inc is rated fourth in number of employees category among related companies. The total workforce of Health Care industry is presently estimated at about 461,700. AbbVie retains roughly 50,000 in number of employees claiming about 11% of equities under Health Care industry.
AbbVie Profit Margins
The company has Profit Margin (PM) of 0.09 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.32 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.32.Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Gross Profit Margin | 0.6 | 0.8384 |
|
| |||||
Net Profit Margin | 0.0851 | 0.0895 |
|
| |||||
Operating Profit Margin | 0.31 | 0.3208 |
|
| |||||
Pretax Profit Margin | 0.11 | 0.1151 |
|
| |||||
Return On Assets | 0.0343 | 0.0361 |
|
|
AbbVie Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific AbbVie insiders, such as employees or executives, is commonly permitted as long as it does not rely on AbbVie's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, AbbVie insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
---|---|---|---|---|---|
2024-03-01 | 1.7317 | 71 | 41 | 1,236,912 | 950,148 |
2023-12-01 | 1.5 | 3 | 2 | 362.00 | 2,912 |
2023-09-01 | 1.0 | 3 | 3 | 438.00 | 120,500 |
2023-06-01 | 1.3636 | 15 | 11 | 39,494 | 61,909 |
2023-03-01 | 1.1667 | 63 | 54 | 1,250,292 | 797,442 |
2022-12-01 | 0.75 | 3 | 4 | 42,655 | 84,740 |
2022-06-01 | 1.25 | 15 | 12 | 247,050 | 450,830 |
2022-03-01 | 1.3673 | 67 | 49 | 1,370,755 | 659,028 |
2021-12-01 | 0.3636 | 8 | 22 | 413,825 | 842,118 |
2021-09-01 | 1.0 | 5 | 5 | 37,738 | 50,467 |
2021-06-01 | 2.125 | 17 | 8 | 110,254 | 185,329 |
2021-03-01 | 2.0 | 62 | 31 | 1,383,091 | 788,590 |
2020-12-01 | 0.3846 | 10 | 26 | 418,063 | 1,077,225 |
2020-09-01 | 1.3333 | 4 | 3 | 8,382 | 60,838 |
2020-06-01 | 3.7778 | 34 | 9 | 177,729 | 83,179 |
2020-03-01 | 4.0 | 68 | 17 | 1,766,677 | 386,511 |
2019-12-01 | 1.0 | 3 | 3 | 828.00 | 6,071 |
2019-09-01 | 1.0 | 11 | 11 | 174,045 | 131,117 |
2019-06-01 | 16.0 | 16 | 1 | 74,597 | 6,375 |
2019-03-01 | 3.3333 | 60 | 18 | 1,210,685 | 293,208 |
2018-12-01 | 0.2917 | 7 | 24 | 230,654 | 531,178 |
2018-09-01 | 1.5 | 3 | 2 | 774.00 | 50,000 |
2018-06-01 | 16.0 | 16 | 1 | 43,760 | 0.00 |
2018-03-01 | 1.4333 | 43 | 30 | 883,854 | 561,860 |
2017-12-01 | 0.9167 | 11 | 12 | 600,023 | 814,144 |
2017-09-01 | 0.1385 | 9 | 65 | 291,044 | 602,252 |
2017-06-01 | 0.5862 | 17 | 29 | 190,318 | 470,027 |
2017-03-01 | 1.0 | 35 | 35 | 1,371,584 | 524,225 |
2016-12-01 | 0.8571 | 6 | 7 | 11,424 | 40,090 |
2016-09-01 | 2.0 | 4 | 2 | 1,712 | 50,755 |
2016-06-01 | 0.3158 | 18 | 57 | 503,614 | 1,085,713 |
2016-03-01 | 0.75 | 15 | 20 | 882,000 | 330,038 |
2015-12-01 | 2.0 | 6 | 3 | 92,903 | 3,430 |
2015-09-01 | 0.1071 | 6 | 56 | 69,368 | 133,825 |
2015-06-01 | 0.2286 | 16 | 70 | 203,507 | 393,890 |
2015-03-01 | 0.875 | 21 | 24 | 1,317,775 | 208,058 |
2014-12-01 | 0.8571 | 6 | 7 | 20,173 | 36,015 |
2014-06-01 | 14.0 | 14 | 1 | 239,852 | 0.00 |
2014-03-01 | 0.4468 | 21 | 47 | 1,087,209 | 186,658 |
2013-12-01 | 1.1 | 11 | 10 | 14,339 | 21,154 |
2013-09-01 | 1.2222 | 33 | 27 | 81,016 | 98,445 |
2013-06-01 | 1.8889 | 17 | 9 | 165,836 | 256,556 |
2013-03-01 | 1.0541 | 39 | 37 | 1,836,941 | 325,131 |
AbbVie Notable Stakeholders
An AbbVie stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as AbbVie often face trade-offs trying to please all of them. AbbVie's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting AbbVie's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Carlos Alban | Vice Chairman, Chief Commercial Officer | Profile | |
Robert Michael | Vice Chairman, Finance and Commercial Operations and Chief Financial Officer | Profile | |
Richard Gonzalez | Chairman, CEO and Chairman of Executive Committee | Profile | |
Jeffrey Stewart | Executive Vice President, Chief Commercial Officer | Profile | |
William Chase | Executive Vice President - Finance and Administration | Profile | |
Azita SalekiGerhardt | Executive Vice President - Operations | Profile | |
Brian Durkin | Vice President Controller | Profile | |
Thomas Hurwich | Vice President Controller | Profile | |
Henry Gosebruch | Executive Vice President Chief Strategy Officer | Profile | |
Timothy Richmond | Chief Human Resource Officer, Executive Vice President | Profile | |
Nicholas Donoghoe | Senior Vice President - Enterprise Innovation | Profile | |
Michael Severino | Executive Vice President - Research & Development, Chief Scientific Officer | Profile | |
Scott Reents | Executive CFO | Profile | |
Laura Schumacher | Executive VP of Bus. Devel. and External Affairs, General Counsel and Corporate Secretary | Profile | |
Brett Hart | Independent Director | Profile | |
Roxanne Austin | Independent Director | Profile | |
Edward Rapp | Independent Director | Profile | |
Frederick Waddell | Independent Director | Profile | |
Robert Alpern | Independent Director | Profile | |
Glenn Tilton | Lead Independent Director | Profile | |
Rebecca Roberts | Independent Director | Profile | |
Edward Liddy | Independent Director | Profile | |
William Burnside | Independent Director | Profile | |
Roy Roberts | Independent Director | Profile | |
Melody Meyer | Independent Director | Profile | |
Perry Siatis | General VP | Profile | |
Sanjay Narayan | Chief SVP | Profile | |
Assil Omar | VP Officer | Profile | |
Azita Gerhardt | Executive Vice President - Operations | Profile | |
Carrie Strom | Senior Vice President AbbVie and President Global Allergan Aesthetics | Profile | |
Thomas Freyman | Independent Director | Profile | |
Thomas MD | Senior Research | Profile | |
Tracie Haas | Brand Responsibility | Profile | |
Thomas Hudson | Senior Vice President Research & Development and Chief Scientific Officer | Profile | |
Greg Miley | Senior Affairs | Profile | |
Elizabeth Shea | Senior Relations | Profile | |
Elaine Sorg | Senior Vice President U.S. Commercial Operations | Profile | |
WulffErik Borcke | Senior Oncology | Profile |
About AbbVie Management Performance
The success or failure of an entity such as AbbVie Inc often depends on how effective the management is. AbbVie management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of AbbVie management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the AbbVie management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | 0.10 | 0.1 | |
Return On Capital Employed | 0.18 | 0.21 | |
Return On Assets | 0.04 | 0.03 | |
Return On Equity | 0.47 | 0.65 |
The data published in AbbVie's official financial statements usually reflect AbbVie's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of AbbVie Inc. For example, before you start analyzing numbers published by AbbVie accountants, it's critical to develop an understanding of what AbbVie's liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of AbbVie's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, AbbVie's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in AbbVie's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of AbbVie Inc. Please utilize our Beneish M Score to check the likelihood of AbbVie's management manipulating its earnings.
AbbVie Workforce Analysis
Traditionally, organizations such as AbbVie use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare AbbVie within its industry.AbbVie Manpower Efficiency
Return on AbbVie Manpower
Revenue Per Employee | 1.1M | |
Revenue Per Executive | 1.4B | |
Net Income Per Employee | 97.7K | |
Net Income Per Executive | 128.5M |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AbbVie Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics. Note that the AbbVie Inc information on this page should be used as a complementary analysis to other AbbVie's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Complementary Tools for AbbVie Stock analysis
When running AbbVie's price analysis, check to measure AbbVie's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AbbVie is operating at the current time. Most of AbbVie's value examination focuses on studying past and present price action to predict the probability of AbbVie's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AbbVie's price. Additionally, you may evaluate how the addition of AbbVie to your portfolios can decrease your overall portfolio volatility.
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios |
Is AbbVie's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AbbVie. If investors know AbbVie will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AbbVie listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.67) | Dividend Share 5.99 | Earnings Share 2.71 | Revenue Per Share 30.723 | Quarterly Revenue Growth (0.05) |
The market value of AbbVie Inc is measured differently than its book value, which is the value of AbbVie that is recorded on the company's balance sheet. Investors also form their own opinion of AbbVie's value that differs from its market value or its book value, called intrinsic value, which is AbbVie's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AbbVie's market value can be influenced by many factors that don't directly affect AbbVie's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AbbVie's value and its price as these two are different measures arrived at by different means. Investors typically determine if AbbVie is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AbbVie's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.